Tjeerd Barf

Tjeerd has extensive experience in pharmaceutical Research and Development and contributed to the delivery of several clinical candidates in the metabolic disease, autoimmune and oncology space. He successfully exploited the covalent binding paradigm for kinases, resulting for instance in the discovery of BTK inhibitor acalabrutinib.

Tjeerd joined the pharmaceutical industry in 1997 and served in various project and line management roles at Pharmacia & Upjohn, Biovitrum, Organon, Schering-Plough and MSD. He is CEO and founder Artica Therapeutics and 3Ceptor Design. Tjeerd co-founded Acerta Pharma and served as the EVP of Chemistry since its inception in 2013. Tjeerd is or was member of the Board of Directors or Scientific Advisory Board for several oncology startup companies, including Cytura Therapeutics, PearlBio and Acerta Pharma.

‍
Tjeerd holds a PhD in Medicinal Chemistry and MSc in Organic Chemistry from the University of Groningen, The Netherlands.